Company intelligence
Glafabra Therapeutics
Gene therapy for Fabry and other enzyme deficiencies - one dose for years long durability and patient freedom
Biotechnology Research
2–10 employees
9 public signals
About Glafabra Therapeutics
Glafabra is a biotherapeutics development company focused on bringing into the clinic our Live-cel(TM) technology for cell-based gene therapy (Cb-GT). Our approach for Fabry Disease provides a 130x improvement in effectiveness for patients, when compared to the standard of care of enzyme replacement therapy. We are bringing to the clinic a therapy that is long acting. Where just one dose, can last for years, not weeks.
Verified activity
Signals from Glafabra Therapeutics
9 published signals
Capital & Finance
Glafabra Therapeutics is considering a capital raise and is testing the waters under Regulation Crowdfunding.
Reported by Glafabra Therapeutics
Legal & Regulatory
Glafabra Therapeutics is considering a capital raise and is
Reported by Glafabra Therapeutics
Capital & Finance
Glafabra Therapeutics is considering a capital raise under Regulation Crowdfunding.
Reported by Glafabra Therapeutics